（编辑 袁冠琳） 证券日报网讯 2月5日，安图生物在互动平台回答投资者提问时表示，公司二级市场股价受行业政策、 宏观经济、资本市场供需及投资者风险偏好等多重因素影响。公司高度重视股价表现与股东关切，但行 业生态修复尚需一定时间。公司将持续聚焦主业，持续加大研发投入，丰富产品线，提升经营质效与核 心竞争力，全面布局精准医疗与智慧医疗，并通过合规渠道加强市场沟通，切实维护全体股东的长远利 益。 ...

（编辑 任世碧） 证券日报网讯 2月5日，安图生物在互动平台回答投资者提问时表示，截至目前，公司AI检验临床辅助 决策系统已在30余家医院安装，并顺利衔接医院现有检验设备及LIS系统，对公司毛利率影响较小。 ...

黄河之滨，天地之中。工业引擎轰鸣，新质生产力加速成长，正为郑州高质量发展注入澎湃动能。 最新统计数据显示，2025年，全市规上工业增加值同比增长9%，超七成行业生产实现增长。其中，电 子信息产业、汽车制造业增加值分别同比增长16.2%、11.9%，贡献突出。以宇通客车、安图生物、超 聚变等为代表的企业，在新能源、生物医药、先进算力等领域"向新而行"，勾勒出郑州工业结构升级、 韧性增强的清晰轨迹，夯实了实体经济根基。 全景扫描：稳中有进的数据版图 经济总量的跃升，源于关键领域扎实稳健的支撑。全市上下全力以赴推政策、扩需求，育新质、转 动能，坚持把保持工业经济快速增长态势作为经济发展压舱石。2025年，全市规上工业增加值同比增长 9%。规上工业38个行业大类中，27个行业增加值保持增长，增长面71.1%，比2024年提高8.9个百分 点。 主导产业拉动有力。规上工业主导产业增加值同比增长9.7%。其中，电子信息产业、汽车制造业 增加值分别同比增长16.2%、11.9%，合计拉动全市规上工业增加值增速6.4个百分点。 标杆力量：领军企业的奋进步履 在奋进前行的画卷中，领军企业是最具象、最生动的笔触。宇通客车、安图生 ...

Group 1: Nipah Virus Detection Products - Wanfu Biology announced the launch of "Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)" to meet the demand for rapid and accurate testing [2] - Kehua Bio stated that its subsidiary has developed a Nipah virus detection kit to support key prevention and control points such as customs and disease control centers [3] - Zhijiang Biology emphasized the importance of early virus isolation and nucleic acid testing due to the non-specific symptoms in early-stage patients, offering a high-sensitivity detection kit [4] - Capbio has developed a Nipah virus detection kit, providing core technical support for global quarantine and disease control monitoring [4] - Shengxiang Biology offers a dual-platform solution for rapid and accurate detection of Nipah virus, with its detection kit already receiving EU CE certification [4] - Antu Biology provides rapid detection support through its fully automated nucleic acid purification and real-time fluorescent PCR analysis system [4] Group 2: Market Reactions and Clarifications - Some A-share companies clarified their positions, stating they do not have any business related to Nipah virus. Hualan Biological announced it has no vaccine products for Nipah virus [5] - Sely Medical confirmed it currently has no Nipah virus testing reagents or treatment drugs in reserve [6] - Other companies like Weixin Kang and CanSino also stated they do not have related products [7]

Core Viewpoint - The recent outbreak of Nipah virus in India has raised public concern, but experts believe it is unlikely to spread on a large scale like COVID-19 [1] Group 1: Company Developments - Multiple companies, including Antu Biology, Shuoshi Biology, Jinhao Pharmaceutical, Kaipu Biology, Zhijiang Biology, Zhongke Shengyi, Weiboxin Biology, and Shengke Yuan Biology, have developed nucleic acid testing reagents for Nipah virus and are actively supporting testing efforts [1] - There is reported procurement demand in relevant regions, although there have been no significant changes domestically; some key ports have a demand for reagent reserves [1] Group 2: Industry Insights - Experts, including Professor Jin Dongyan from the University of Hong Kong, suggest that Nipah virus is not a new virus and has caused small outbreaks with single-digit cases almost every year for the past two decades [1] - The current situation is not significantly different from previous years, and the virus has a low incidence of asymptomatic infections, allowing for effective control through isolation [1]

【导读】印度尼帕病毒疫情引关注，相关概念股大涨，多家公司紧急回应 据悉，尼帕病毒感染潜伏期为3至14天，初期症状与流感相似，易出现误诊。这也意味着，早期精准检 测不仅能为临床干预争取时间，也是落实国境检疫、疫情溯源的核心环节。 随着尼帕病毒疫情持续发酵，市场对病毒防治、体外诊断等相关概念股的关注明显升温。截至1月27日 收盘，相关板块个股集体走强，凯普生物、达安基因斩获两连板；拓新药业、利德曼、特一药业等个股 涨幅居前。 | 凯普生物 | 8.70 | 20.00% | 1.45 | | --- | --- | --- | --- | | 300639 | | | | | ■正米 (天2板 入气龙头- 激电人 2020年半年频型示公司目主研发的 | | | | | 新型冠状病毒(2019-nCaV)核酸检测试刊盒(艾光PCR法)以新型冠状 ... | | | | | 达安惠因 | 7.71 | 9.99% | 0.70 | | 002030 @ | | | | | ■更新 2天2板 人气息头三 周期人用 多种药毒检测服务 | | | | | 拓新药业 | | 34.37 7.98% | 2.54 | | 30 ...

Group 1 - The recent outbreak of Nipah virus disease in West Bengal, India, has raised significant concern, with 5 confirmed cases reported, including healthcare workers, and nearly 100 individuals under home quarantine [1] - The impact of the Nipah virus outbreak on China is relatively minor, with no cases reported in the country, although there is a risk of imported cases that necessitates enhanced preventive measures [1][2] - Nipah virus has been known for over 20 years, with its first outbreak occurring in Malaysia in 1998, and it primarily affects South Asia and Southeast Asia [1][2] Group 2 - The Nipah virus primarily damages the central nervous system (90%) and respiratory system (62%), with a high fatality rate ranging from 40% to 75% [2] - Experts indicate that the Nipah virus has a low basic reproduction number (R₀) compared to influenza or COVID-19, and there have been no reports of large-scale airborne transmission [4] - Current antiviral treatments for Nipah virus are limited, with no approved drugs or vaccines available, although Ribavirin may be effective for treating Nipah virus encephalitis [4][5] Group 3 - Recent research has shown that VV116 has antiviral activity against Nipah virus in vitro and can improve survival rates in mouse models, indicating potential for treatment [4][5] - Several companies have reported possessing Nipah virus testing technology or products, but they have not yet achieved significant revenue from these offerings [6] - The most common testing method for Nipah virus is nucleic acid testing, and public health departments are equipped to handle such testing, which is deemed sufficient for current needs [6]

Group 1 - The Nipah virus outbreak in West Bengal, India has confirmed 5 cases with nearly 100 people under observation, prompting neighboring countries like Thailand and Nepal to enhance health screening for travelers from India [1] - The World Health Organization (WHO) classifies the Nipah virus as a high-priority regional threat due to its high mortality rate of 40%-70% and the absence of approved vaccines or treatments [4][11] - The research team from Wuhan Institute of Virology has published findings indicating that the oral nucleoside drug VV116 shows significant antiviral activity against the Nipah virus, providing new hope for treatment [2][8] Group 2 - VV116, developed by Wangshan Wangshui and Junshi Biosciences, has shown potential against various RNA viruses, including the Nipah virus, and has been approved for COVID-19 treatment in China and Uzbekistan [7][8] - Following the announcement of VV116's efficacy against the Nipah virus, shares of Wangshan Wangshui surged by 10.9%, reaching a new high since its listing in November 2025 [4][5] - The market response to the Nipah virus outbreak has led to significant stock price increases for several companies involved in diagnostic testing, with companies like Kaipu Biological and Da'an Gene reporting substantial gains [12][13]

Core Viewpoint - The Nipah virus outbreak in India has prompted several A-share listed companies, including BGI Innovation, Capbio, and Antu Biology, to announce their capabilities in Nipah virus testing, although they have not yet achieved significant revenue from these products [1] Group 1: Company Responses - Antu Biology stated that the demand for its Nipah virus testing products cannot be estimated at this early stage of the outbreak in India, and its overseas market presence is relatively small [1] - Capbio acknowledged its technical capability to detect the Nipah virus, but indicated that commercialization is not yet underway and will require time to implement outside of emergency situations [1]

Core Viewpoint - The article highlights the outbreak of Nipah virus in West Bengal, India, and emphasizes the critical role of rapid and accurate testing in epidemic prevention and monitoring, given the virus's high mortality rate of 40%-75% and the absence of effective vaccines or treatments [3]. Group 1: Industry Response - Companies such as Capbio, Shuoshi Bio, and Zhongke Shengyi have quickly responded to the Nipah virus outbreak by providing testing kits to aid in epidemic monitoring and prevention [4]. - The Nipah virus is classified as a newly emerging zoonotic virus, causing severe diseases characterized by encephalitis or respiratory illnesses in infected individuals [6]. Group 2: Product Offerings - Capbio offers a range of Nipah virus nucleic acid testing kits using fluorescence PCR methods, with various packaging options available [11]. - The testing kits include specifications for different sample types such as serum, plasma, throat swabs, whole blood, urine, and viral cultures, with a detection limit of 500 copies/mL and a report time of 70 minutes [18].